PT109

PT109 is a multi-kinase inhibitor. PT109 inhibits JNK (JNK1: IC50=0.143 μM; JNK2: IC50=0.831 μM; JNK3: IC50=0.285 μM) and other kinases (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM; ROCK2: IC50=34 μM) and plays an important role in anti-inflammation, anti-oxidation, neurogenesis, synaptogenesis, etc. In addition, PT109 also reprograms glioblastoma multiforme (GBM) into oligodendrocytes through the PTBP1/PKM1/2 pathway and changes the metabolic pattern of GBM, exerting anti-glioma activity[1][2].

Product Specifications

CAS Number

[2059104-90-2]

UNSPSC

12352005

Target

JNK; ROCK; SGK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pt109.html

Purity

99.20

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(CCCCC1SSCC1)NC2CCC(CC2)NC3=CC=CC4=C3C=CN=C4

Molecular Formula

C23H31N3OS2

Molecular Weight

429.64

References & Citations

[1]Chen Q, et al. Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo[J]. European Journal of Pharmacology, 2020, 883: 173361.|[2]Yang Y, et al. PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway[J]. European Journal of Pharmacology, 2022, 920: 174837.